

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q3 16-17	Q3 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
Formulations Business - Key Markets	18,635	19,403	-4.0%	56,725	57,722	-1.7%
US Formulations	8,869	10,717	-17.2%	27,240	30,605	-11.0%
India Formulations	7,968	7,198	10.7%	24,039	22,136	8.6%
Latin America Formulations	659	544	21.1%	1,842	1,624	13.4%
Emerging Markets Formulations	1,139	944	20.6%	3,604	3,357	7.4%
Other Businesses and Alliances	4,389	3,778	16.2%	12,790	11,669	9.6%
Europe Formulations	653	761	-14.1%	2,002	2,245	-10.8%
Consumer Wellness	1,113	1,111	0.2%	3,393	3,186	6.5%
Animal Health & Others	1,134	785	44.4%	3,456	2,354	46.8%
APIs	1,053	838	25.7%	2,861	2,724	5.0%
Alliances	435	282	53.9%	1,077	1,160	-7.2%
Grand Total	23,024	23,181	-0.7%	69,515	69,391	0.2%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q3 16-17	Q3 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
Other Operating Income	614	908	-32.4%	1,490	2,907	-48.8%
Export Incentive	178	348	-48.9%	645	880	-26.7%
Royalty Income	16	68	-75.6%	66	169	-60.7%
Net Gain on foreign currency transactions and translation (Refer Note below)	107	118	-9.7%	193	304	-36.5%
Others	313	375	-16.4%	585	1,555	-62.4%

Note : There was a net gain of Rs. 97 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods in Q3 16-17. Thus, on aggregate level, there was a gain of Rs. 203 Mio. on operating transactions (above EBIDTA line) in Q3 16-17 vs gain of Rs. 211 Mio. in Q3 15-16. See details below for more clarity.

Rs. Mio.	Q3 16-17	Q3 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
Other Income	166	323	-48.6%	555	763	-27.3%
Interest & Dividend income	114	153	-25.3%	416	459	-9.5%
Profit on sale of investments	20	148	-86.3%	72	197	-63.3%
Others	31	22	43.1%	67	106	-37.0%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q3 16-17	Q3 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
A. On operating transactions (above EBIDTA line)	-203	-211	3.8%	-407	-695	41.4%
a. Included in other income	-107	-118	9.7%	-193	-304	36.5%
b. Included in cost of goods	-97	-93	-3.8%	-214	-391	45.3%
B. On Foreign Currency Borrowings (part of interest cost)	-63	15	-520.0%	-26	44	-159.1%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	-266	-196	-35.7%	-433	-651	33.5%

Details of R&D Expenses

Rs. Mio.	Q3 16-17	Q3 15-16	% Gr y-y	YTD 16-17	YTD 15-16	% Gr y-y
Total R&D Expenses	2,210	2,368	-6.7%	5,359	5,782	-7.3%

Consolidated Capex for Apr - Dec 16

Rs. 16195
Mio.

R&D capex included in above for Apr - Dec 16

Rs. 218
Mio.